ISSN:
1569-8041
Schlagwort(e):
chemotherapy
;
CHVmP-VB
;
EORTC
;
intermediate/high-grade
;
non-Hodgkin's lymphoma
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Abstract CHOP has been and still is regarded by many as the ‘standard’ treatment ofadvanced non-Hodgkin's lymphoma. In 1980 the EORTC Lymphoma Cooperative Groupstarted a study to evaluate the addition of vincristine and bleomycin to itsstandard four-drug combination chemotherapy, CHVmP (cyclophosphamide,hydroxorubicin, Vm-26, prednisone). Eligible patients were stage III or IV,intermediate- to high-grade non-Hodgkin's lymphoma (Working FormulationE–I). One-hundred-eighty-nine patients were entered, of whom 140 were eligibleand evaluable. A previous report showed an improved response rate andfailure-free survival (FFS) and overall survival for the combination CHVmP-VB. At ten years, the outcome still favors the addition of vincristine andbleomycin. The FFS was 34% vs. 23% and the overall survival34% vs.22%. This difference was mainly due to a difference in CR rate(74% vs.49%), Relapse-free survival for patients reaching a CR was the same inboth arms. When the patients were grouped according to the International PrognosticFactor Index, no statistically significant difference could be observed infavor of one treatment within either group. This trial clearly demonstrates the benefit gained by the addition ofvincristine and bleomycin to ‘standard’ chemotherapy for intermediate andhigh-grade non-Hodgkin's lymphoma.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1023/A:1008210102316
Permalink
